Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
Lykke M Ørnbjerg,Kathrine Rugbjerg,Stylianos Georgiadis,Simon H Rasmussen,Lennart Jacobsson,Anne G Loft,Florenzo Iannone,Karen M Fagerli,Jiri Vencovsky,Maria J Santos,Burkhard Möller,Manuel Pombo-Suarez,Ziga Rotar,Bjorn Gudbjornsson,Ayse Cefle,Kari Eklund,Catalin Codreanu,Gareth Jones,Marleen van der Sande,Johan K Wallman,Marco Sebastiani,Brigitte Michelsen,Jakub Závada,Michael J Nissen,Carlos Sanchez-Piedra,Matija Tomšič,Thorvardur J Love,Heikki Relas,Corina Mogosan,Merete L Hetland,Mikkel Østergaard,Lykke M. Ørnbjerg,Simon H. Rasmussen,Anne G. Loft,Karen M. Fagerli,Maria J. Santos,Johan K. Wallman,Michael J. Nissen,Thorvardur J. Love,Merete L. Hetland
DOI: https://doi.org/10.3899/jrheum.2023-0764
2024-01-15
The Journal of Rheumatology
Abstract:Objective To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)– adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.
rheumatology